Results 1 to 10 of about 165,940 (211)

Use of Antihypertensive Agents and Association With Risk of Adverse Outcomes in Chronic Kidney Disease: Focus on Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
Background Our objective was to determine patterns of antihypertensive agent use by stage of chronic kidney disease (CKD) and to evaluate the association between different classes of antihypertensive agents with nonrenal outcomes, especially in advanced ...
Elaine Ku, Charles E. McCulloch, Eric Vittinghoff, Feng Lin, Kirsten L. Johansen   +4 more
doaj   +3 more sources

Regression of a venous malformation during angiotensin-converting enzyme inhibitor treatment for hypertension [PDF]

Journal of Vascular Surgery Cases and Innovative Techniques, 2022
Recent studies have reported that components of the renin-angiotensin system (RAS) are expressed in venous malformations by embryonic stem cell-like subpopulations.
Sigurd Berger, MD, Therese Halvorsen Bjark, MD, Karsten Midtvedt, MD, PhD, Rune Andersen, MD   +3 more
doaj   +2 more sources

Tranexamic acid for angiotensin-converting enzyme inhibitor–induced angioedema [PDF]

Clinical and Experimental Emergency Medicine
Approximately 0.7% of patients taking angiotensin-converting enzyme inhibitors (ACEIs) develop ACEI-induced angioedema (ACEI-IA). With no approved treatments for ACEI-IA, the risk of complications is concerning. Tranexamic acid (TXA) has the potential to
Gaurav Nitin Pathak, Thu Minh Truong, Abhishek Chakraborty, Babar Rao, Catherine Monteleone   +4 more
doaj   +2 more sources

Association between angiotensin-converting enzyme inhibitor-induced cough and the risk of lung cancer: a Mendelian randomization study [PDF]

Frontiers in Pharmacology, 2023
Background: Observational studies and meta-analyses have demonstrated a positive correlation between the use of angiotensin-converting enzyme inhibitors (ACEIs) and lung cancer.
Taikang Yao, Taikang Yao, Zhenchao Wu, Zilu Wang, Zilu Wang, Liting Chen, Liting Chen, Beibei Liu, Ming Lu, Ning Shen   +9 more
doaj   +2 more sources

EFFICACY OF A NON-LIPOPHILIC ANGIOTENSIN CONVERTING ENZYME INHIBITOR AND ITS POSSIBLE ADVANTAGES

Российский кардиологический журнал, 2003
Efficacy of a non-lipophilic angiotensin converting enzyme inhibitor and its possible advantages.
N. A. Mazur
doaj   +1 more source

Retrospective evaluation of risk factors for worsening renal function after angiotensin-converting enzyme inhibitor treatment in dogs. [PDF]

J Vet Intern Med
Lee Y, Baek M, Lee D, Park J, Chae Y, Kang BT, Yun T, Kim H.   +7 more
europepmc   +2 more sources

Angiotensin-converting Enzyme Inhibitors: Can it be a Potential Treatment of Infantile Hemangioma

Journal of Indian Association of Pediatric Surgeons, 2021
Aims: The aim of the sudy was to evaluate potential role of oral captopril, an angiotensin-converting enzyme (ACE) inhibitor, and in treatment of infantile hemagioma (IH) and report our preliminary results.
Archika Gupta, Shiv Narain Kureel, Anand Pandey, Gurmeet Singh, Akhilesh Kumar, Gaurav Shandilya, Rahul Kumar Rai, Survesh Kumar Gupta   +7 more
doaj   +1 more source

Antecedent Administration of Angiotensin‐Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID‐19 Syndrome

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Background Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) utilizes the angiotensin‐converting enzyme‐2 (ACE‐2) receptor to enter human cells.
Alberto Palazzuoli, Massimo Mancone, Gaetano M. De Ferrari, Giovanni Forleo, Gioel G. Secco, Gaetano M. Ruocco, Fabrizio D'Ascenzo, Silvia Monticone, Anita Paggi, Marco Vicenzi, Anna G. Palazzo, Maurizio Landolina, Erika Taravelli, Guido Tavazzi, Francesco Blasi, Fabio Infusino, Francesco Fedele, Francesco G. De Rosa, Michael Emmett, Jeffrey M. Schussler, Kristen M. Tecson, Peter A. McCullough   +21 more
doaj   +1 more source

Renin‐Angiotensin Aldosterone System Inhibitors and COVID‐19: A Systematic Review and Meta‐Analysis Revealing Critical Bias Across a Body of Observational Research

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background Renin‐angiotensin aldosterone system (RAAS) inhibitor—COVID‐19 studies, observational in design, appear to use biased methods that can distort the interaction between RAAS inhibitor use and COVID‐19 risk. This study assessed the extent of bias
Jordan Loader, Frances C. Taylor, Erik Lampa, Johan Sundström   +3 more
doaj   +1 more source

Incidence of angiotensin-converting enzyme inhibitor-induced cough in a Malaysian public primary care clinic: A retrospective cohort study [PDF]

Malaysian Family Physician, 2022
Introduction: The incidence of angiotensin-converting enzyme inhibitors (ACEi)-induced cough has been reported between 5% and 30% but is unknown in Malaysia.
Hou Chan Loo, Fairuz Osman, Siew Lee Ho, Sing Yee An, Yim Mei Au Yong, Ee Ming Khoo   +5 more
doaj   +1 more source